What does the Humira experience mean for future biosimilar markets?
The Humira playbook — patent thickets, PBM private labels, formulary control, list-price cuts and patient switching — is now the template for the next biologics facing the patent cliff, with the key open question being whether reforms produce genuine price competition or merely transfer profits from manufacturers to PBMs.
The Humira market has become the template for what happens when a blockbuster biologic loses exclusivity in the US. Its lessons are that patent thickets and settlements can delay competition for years; that rebate-driven formularies can keep biosimilar uptake near zero until a PBM acts; and that when PBMs do act, they may favour their own private labels. As one analysis put it, the "Humira playbook", comprising PBM private label, formulation matching and aggressive list-price cuts, is the template for the next biologics facing the patent cliff. Policymakers are considering patent reform, FDA streamlining of biosimilar approvals, and PBM reforms such as those in the FTC's insulin settlements. Whether these produce genuine price competition, rather than a transfer of profits from manufacturers to PBMs, is the key open question.